Suzhou Zelgen Biopharmaceuticals (SHA:688266) presented two cancer drugs at the American Society of Clinical Oncology, according to a Shanghai bourse filing on Tuesday.
The drugs presented were Nilvanstomig, which was developed as a treatment for hepatocellular carcinoma, and Alveltamig, a T-cell engager immunotherapy.
Both drugs showed safety profiles during the clinical trials.